Answers are grounded in this paper and cite their sources.
Relapsed/refractory multiple myeloma (RRMM) poses substantial therapeutic challenges, and chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment modality. However, CAR-T therapy is often complicated by life-threatening adverse events, most notably cytokine release syndrome (CRS) and secondary hemophagocytic lymphohistiocytosis(sHLH). However distinguishing atypical Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome(IEC-HS) from conventional CRS or sHLH remains clinically difficult but is critical for patient survival. Their overlapping clinical manifestations frequently complicate accurate diagnosis and clinical management. Here, we report a patient who developed an extremely elevated interleukin-6 (IL-6) level (1,227,475 pg/mL) during CAR-T therapy and concurrently met all key diagnostic criteria for sHLH, leading to a diagnosis of severe CRS complicated with sHLH, which was atypical IEC-HS. After three courses of tocilizumab treatment proved ineffective, therapeutic plasma exchange (TPE) was performed and successfully alleviated the severe adverse events associated with CAR-T therapy. These findings indicate that TPE represents a viable therapeutic option for the atypical IEC-HS following CAR-T infusion. We comprehensively explored the diagnosis of CRS combined with sHLH in RRMM patients after CAR-T therapy through the treatment process of individual cases, with a focus on analyzing the therapeutic effect of plasma exchange. This review aims to provide evidence-based guidance and decision support for clinicians to manage these complex and potentially fatal complications, ultimately improving the prognosis of patients with atypical IEC-HS in RRMM after CAR-T therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: